CU23581A1 - Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer - Google Patents

Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer

Info

Publication number
CU23581A1
CU23581A1 CU20050207A CU20050207A CU23581A1 CU 23581 A1 CU23581 A1 CU 23581A1 CU 20050207 A CU20050207 A CU 20050207A CU 20050207 A CU20050207 A CU 20050207A CU 23581 A1 CU23581 A1 CU 23581A1
Authority
CU
Cuba
Prior art keywords
autoimmune
treatment
allergic
alfa
ficocianine
Prior art date
Application number
CU20050207A
Other languages
English (en)
Inventor
Nieto Gerardo Enrique Guillen
Rol Giselle Penton
Silva Carmen Maria Valenzuela
Llanos Majel Cervantes
Arias Eduardo Penton
Del Barco Herrera Diana Garcia
Saura Pedro Antonio Lopez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20050207A priority Critical patent/CU23581A1/es
Priority to BRPI0617943A priority patent/BRPI0617943A2/pt
Priority to CA2627531A priority patent/CA2627531C/en
Priority to PCT/CU2006/000012 priority patent/WO2007048357A1/es
Priority to KR1020087012864A priority patent/KR20080066060A/ko
Priority to ARP060104737A priority patent/AR057565A1/es
Priority to AU2006308342A priority patent/AU2006308342A1/en
Priority to EP06805255A priority patent/EP1955706A1/en
Priority to JP2008536916A priority patent/JP2009513583A/ja
Priority to US12/091,776 priority patent/US8110182B2/en
Priority to CNA2006800491488A priority patent/CN101355958A/zh
Priority to RU2008121248/15A priority patent/RU2008121248A/ru
Priority to ZA200804609A priority patent/ZA200804609B/xx
Publication of CU23581A1 publication Critical patent/CU23581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención consiste en la combinación de interferón alfa y C- Ficocianina (IFN-alfa / C-Fico) en la obtención de una preparacíon farmacéutica para el tratamiento de enfermedades autoinmunes, alérgicas y el cáncer. Los efectos antinflamatorios, inmunomoduladores, antioxidantes, antivirales, antiproliferativos, antitumorales, asociados al efecto inductor de células T reguladoras que se demuestra en esta invención, hacen racional el uso de la combinación IFN-alfa / C-Fico en estas enfermedades.
CU20050207A 2005-10-28 2005-10-28 Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer CU23581A1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CU20050207A CU23581A1 (es) 2005-10-28 2005-10-28 Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
BRPI0617943A BRPI0617943A2 (pt) 2005-10-28 2006-10-30 composto farmacêutico e uso de um composto farmacêutico
CA2627531A CA2627531C (en) 2005-10-28 2006-10-30 Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer
PCT/CU2006/000012 WO2007048357A1 (es) 2005-10-28 2006-10-30 Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
KR1020087012864A KR20080066060A (ko) 2005-10-28 2006-10-30 자가면역 질환, 알레르기 질환 및 암의 치료를 위한인터페론-알파 및 ｃ-피코시아닌
ARP060104737A AR057565A1 (es) 2005-10-28 2006-10-30 Interferon alfa y c- ficocianina para el tratamiento de enfermedades auoinmunes alergicas y cancer
AU2006308342A AU2006308342A1 (en) 2005-10-28 2006-10-30 Interferon-alpha and C-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer
EP06805255A EP1955706A1 (en) 2005-10-28 2006-10-30 Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer
JP2008536916A JP2009513583A (ja) 2005-10-28 2006-10-30 自己免疫疾患、アレルギー性疾患及び癌の治療用インターフェロン−アルファ及びｃ−フィコシアニン
US12/091,776 US8110182B2 (en) 2005-10-28 2006-10-30 Treatment of multiple sclerosis by administration of interferon alpha and C-phycocyanin
CNA2006800491488A CN101355958A (zh) 2005-10-28 2006-10-30 用于治疗自身免疫疾病、过敏反应和癌症的干扰素α和C-藻蓝蛋白
RU2008121248/15A RU2008121248A (ru) 2005-10-28 2006-10-30 Интерферон альфа и с-фикоцианин для лечения аутоиммунных заболеваний, аллергии и рака
ZA200804609A ZA200804609B (en) 2005-10-28 2008-05-27 Interferon-alpha and C-phycocyanin for the treatment of autoimmune diseases, allergic disease sand cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050207A CU23581A1 (es) 2005-10-28 2005-10-28 Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer

Publications (1)

Publication Number Publication Date
CU23581A1 true CU23581A1 (es) 2010-10-30

Family

ID=37748615

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050207A CU23581A1 (es) 2005-10-28 2005-10-28 Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer

Country Status (13)

Country Link
US (1) US8110182B2 (es)
EP (1) EP1955706A1 (es)
JP (1) JP2009513583A (es)
KR (1) KR20080066060A (es)
CN (1) CN101355958A (es)
AR (1) AR057565A1 (es)
AU (1) AU2006308342A1 (es)
BR (1) BRPI0617943A2 (es)
CA (1) CA2627531C (es)
CU (1) CU23581A1 (es)
RU (1) RU2008121248A (es)
WO (1) WO2007048357A1 (es)
ZA (1) ZA200804609B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101716332B (zh) * 2009-11-12 2012-03-07 中国药科大学 藻蓝蛋白用于防治糖尿病的用途
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
IT1403990B1 (it) * 2010-12-16 2013-11-08 Associazione Termalisti Isola D Ischia Cianobatterio della famiglia delle pseudanabaenaceae (oscillatoriales, cyanophyta), genere protolyngbya, specie protolyngbya sp. ceppo itd-01
CU23963B1 (es) * 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
US20140314890A1 (en) * 2011-10-31 2014-10-23 The Florida International University Board Of Trustees Combination anti-cancer therapy
CN108676774B (zh) 2011-12-01 2023-05-09 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
KR102115854B1 (ko) * 2017-11-13 2020-05-27 인하대학교 산학협력단 조류 색소 단백질을 포함하는 염증성 피부 질환 예방 또는 치료용 조성물
CN113198006B (zh) * 2021-05-12 2022-05-03 国珍健康科技（北京）有限公司 具有抑制lps诱导巨噬细胞分泌no功能的组成物及其应用和免疫药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865216A (ja) 1981-09-16 1983-04-18 Dainippon Ink & Chem Inc 抗腫瘍剤
US5163898A (en) * 1987-03-16 1992-11-17 The Regents Of The University Of California Medical treatment of tumors with phycocyanin

Also Published As

Publication number Publication date
BRPI0617943A2 (pt) 2016-10-25
CA2627531A1 (en) 2007-05-03
KR20080066060A (ko) 2008-07-15
ZA200804609B (en) 2009-02-25
US20090280087A1 (en) 2009-11-12
AU2006308342A1 (en) 2007-05-03
RU2008121248A (ru) 2009-12-10
WO2007048357A1 (es) 2007-05-03
EP1955706A1 (en) 2008-08-13
JP2009513583A (ja) 2009-04-02
AR057565A1 (es) 2007-12-05
CN101355958A (zh) 2009-01-28
US8110182B2 (en) 2012-02-07
CA2627531C (en) 2012-03-20

Similar Documents

Publication Publication Date Title
CU23581A1 (es) Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
CY1123387T1 (el) Συνδυασμος δυο αντιιικων για τη θεραπεια της ηπατιτιδας c
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
CO2020009625A2 (es) Inhibidor de fap
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
CR8273A (es) Administracion de ligandos de tlr7 y profarmacos de los mismos para el tratamiento de la infeccion por el virus de hepetitis c
UY33616A (es) Compuestos con estructura de imidazotriazinona
MX2020009757A (es) Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.
SV2015004969A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
ECSP056114A (es) Combinaciones antineoplásicas
ECSP109934A (es) Compuesto - 946
PA8740901A1 (es) Compuestos organicos
HN2002000266A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
CY1113160T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CY1107253T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2h-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
UY31236A1 (es) Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]-piridazina, su preparacion y su aplicacion en terapéutica
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
UY29876A1 (es) Derivados de acidos dicarboxilicos y su uso
CY1124832T1 (el) 7-βενζυλο-4-(2-μεθυλοβενζυλο)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1 η)-ονη, τα αλατα της και οι μεθοδοι χρησης τους σε συνδυαστικη θεραπεια
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
AR052165A1 (es) Tratamiento de hepatitis c en la poblacion asiatica